Fig. 1: Progression-free survival (PFS) curves in patients treated with paclitaxel and bevacizumab calculated by the Kaplan–Meier method, according to the favorable (blue line) and unfavorable (green line) genetic profiles, with the adjusted hazard ratio (HR).
CI confidence interval.
